Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management

Annals of Oncology

Volumn 21, Issue SUPPL. 5, 2010, Pages

  Mandala M ^a   Falanga, A ^a   Roila, F ^b  

^a OSPEDALI RIUNITI   (Italy)

^b S MARIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; STREPTOKINASE; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; WARFARIN;

ARTICLE; BRAIN DISEASE; BRAIN HEMORRHAGE; CANCER STAGING; CANCER SURGERY; CENTRAL VENOUS CATHETERIZATION; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DIGESTIVE SYSTEM ULCER; EUROPE; GASTROINTESTINAL ENDOSCOPY; GYNECOLOGICAL EXAMINATION; HORMONAL THERAPY; HUMAN; IMMOBILIZATION; INCIDENCE; INDIVIDUALIZATION; INTERNATIONAL NORMALIZED RATIO; MALIGNANT HYPERTENSION; MALIGNANT NEOPLASTIC DISEASE; MEDICAL SOCIETY; OCCULT BLOOD; PARTIAL THROMBOPLASTIN TIME; PERICARDITIS; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RECOMMENDED DRUG DOSE; RISK FACTOR; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; TREATMENT DURATION; URINALYSIS; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM;

EUROPE; GENERAL SURGERY; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INCIDENCE; NEOPLASMS; PROGNOSIS; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VITAMIN K; WARFARIN;

EID: 77954325044     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq199     Document Type: Article

References (10)

1. Chew HK, Wun T, Harvey D et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers Arch Intern Med 2006; 166: 458-464.
2. Falanga A, Zacharski L. Deep vein thrombosis in cancer: the scale of the problem and approaches to management. Ann Oncol 2005; 16: 696-701.
3. Nalluri SR, Chu D, Keresztes R et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300: 2277-2285.
4. Khorana AA, Kuderer NM, Culakova E et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 15: 4902-4907.
5. Mandala M, Falanga A, Piccioli A et al. Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM). Crit Rev Oncol Hematol 2006; 59: 194-204.
6. Lyman GH, Khorana AA, Falanga A et al. American Society of Clinical Oncology. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-5505.
7. Lee A, Levine M, Baker RI et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153.
8. Meyer G, Marjanovic Z, Valcke J et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162: 1729-1735.
9. Prandoni P, Lensing AW, Piccioli A et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-3488.
10. Carrier M, Le Gal G, Cho R et al. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost 2009; 7: 760-765.